Cargando…
Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate‐specific antigen level and improvement in radiographic findings
INTRODUCTION: In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet. CASE PRESENTATION: A 76‐year‐old man was initially referred...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292163/ https://www.ncbi.nlm.nih.gov/pubmed/32743396 http://dx.doi.org/10.1002/iju5.12062 |